Investment Analysts’ Weekly Ratings Updates for Apnimed (APMD)

A number of firms have modified their ratings and price targets on shares of Apnimed (NASDAQ: APMD) recently:

• 8/25/2026 – Apnimed is now covered by Evercore Inc. They set an “outperform” rating on the stock.
• 8/25/2026 – Apnimed is now covered by Lifesci Capital. They set an “outperform” rating and a $50.00 price target on the stock.
• 8/25/2026 – Apnimed is now covered by Bank of America Corporation. They set a “buy” rating and a $41.00 price target on the stock.
• 8/25/2026 – Apnimed is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $60.00 price target on the stock.
• 8/8/2026 – Apnimed was upgraded by Wall Street Zen to “hold”.

Insider Buying and Selling at Apnimed

In other Apnimed news, major shareholder Morningside Venture Investment purchased 312,500 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were bought at an average price of $16.00 per share, with a total value of $5,000,000.00. Following the completion of the acquisition, the insider owned 7,152,713 shares in the company, valued at approximately $114,443,408. This represents a 4.57% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Apnimed Inc is a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies which address the neurobiology of sleep-related breathing diseases. Apnimed Inc is based in CAMBRIDGE, Mass.